As the hour crept past three in the afternoon, New Orleans’ French Quarter was devoid of tourists and locals alike. The heat index was over 105 degrees.
How Biocon Biologics is taking on the US biosimilars market
Biocon Biologics is betting big that it can be a top US biosimilars company. With its $3 billion acquisition of Viatris’ biosimilar portfolio last November